Photochemical eradication of methicillin-resistant Staphylococcus aureus by blue light activation of riboflavin
2017 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 95, no 5, p. 498-502Article in journal (Refereed) Published
Abstract [en]
Purpose: To compare elimination of methicillin-resistant Staphylococcus aureus (MRSA) by exposure of blue light alone and with riboflavin.
Methods: A reference strain of MRSA was cultured and diluted in PBS with and without riboflavin (0.01%). Fifteen microlitre was added on a microscope slide, creating a fluid layer with a thickness of around 400 microns. Both of the bacterial suspensions were exposed to blue light, and the effect between exposure with and without riboflavin was compared. Evaluation involved two different wavelengths (412 and 450 nm) of blue light with a lower (5.4 J/cm(2) ) and higher dose (approximately 28.5 J/cm(2) ). The effect of 412 nm light was also evaluated for a thicker fluid layer (1.17 mm). After exposure, colony-forming units (CFUs) were determined for each solution. All measurements were repeated eight times.
Results: The reductions in bacteria were similar for both wavelengths. With riboflavin, a statistically significant elimination was observed for both 412 and 450 nm (p < 0.001). At both dosages, the mean reduction was more pronounced with the presence of riboflavin than without it. Using the higher dose, CFU reduction was 99% and 98%, respectively, for 412 and 450 nm light. The bactericidal efficacy was high also in the deeper fluid layer (93%, higher dose).
Conclusion: Riboflavin enhanced the antibacterial effect on the exposed MRSA strain of blue light for both 412 and 450 nm blue light. This indicates that blue light could be considered for possible implementation in deep corneal infections.
Place, publisher, year, edition, pages
Hoboken, USA: Wiley-Blackwell Publishing Inc., 2017. Vol. 95, no 5, p. 498-502
Keywords [en]
Keratitis, riboflavin, blue light, PACK-CXL, collagen cross-linking
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:oru:diva-55956DOI: 10.1111/aos.13409ISI: 000405388500027PubMedID: 28205348Scopus ID: 2-s2.0-85013230688OAI: oai:DiVA.org:oru-55956DiVA, id: diva2:1080641
Note
Funding Agencies:
Örebro University Hospital (Sweden) OLL-294081 fOLL-393791
2017-03-102017-03-102020-12-01Bibliographically approved